Investment Summary

EQT Life Sciences Invests In Egle

On October 22, 2021, growth capital firm EQT Life Sciences invested in life science company Egle

Investment Highlights
  • This is EQT Life Sciences’ 26th transaction in the Life Science sector.
  • This is EQT Life Sciences’ 4th transaction in France.

Investment Summary

Date 2021-10-22
Target Egle
Sector Life Science
Investor(s) EQT Life Sciences
Deal Type Venture

Target

Egle

Paris, France
Egle is a biotechnology company focused on developing first in class T-regulatory cell therapies based on Treg-starvers for oncology and autoimmune diseases. Egle was founded in 2020 and is based in Paris, France.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

EQT Life Sciences


Category Growth Capital Firm
Founded 1987
PE ASSETS 3.5B EUR
Size Large
Type Sector Focused
DESCRIPTION

EQT Life Sciences (formerly Life Science Partners) is a private investment firm focused on growth and venture capital financing for life sciences and healthcare companies. The Firm targets early to mid?stage companies in sectors such as therapeutics, medical devices, diagnostics, healthtech, and biotech. EQT Life Sciences was formed in 1986 and is headquartered in Amsterdam, the Netherlands.


DEAL STATS #
Overall 42 of 47
Sector: Life Science M&A 26 of 30
Type: Venture M&A Deals 36 of 39
Country: France M&A 4 of 4
Year: 2021 M&A 10 of 12
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-09-16 Amolyt Pharma

Ecully, France

Amolyt Pharma is a clinical-stage biotechnology company, building therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Amolyt Pharma was founded in 2015 and is based in Ecully, France.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-11-30 HotSpot Therapeutics

Boston, Massachusetts, United States

HotSpot Therapeutics is a biotechnology company focused on discovering nature’s regulatory sites to advance allosteric drug discovery. HotSpot Therapeutics was formed in 2017 and is based in Boston, Massachusetts.

Buy -